LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event will bring together students, faculty, and participants from systems engineering and healthcare-related academic communities, including pharmacy, dentistry, and laboratory sciences, to examine practical applications of AI and automation.
LataMed AI will be represented by Dr. Kevin Rodan Levy, CEO, and Carlos Pena, CFO. Their presentation will address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making. The company intends to discuss how AI-supported tools can assist healthcare professionals with medical data evaluation, clinical workflows, and operational decision-making, and how automation may support the organization, reliability, and efficiency of technology systems in healthcare and other complex environments.
A key emphasis will be on maintaining qualified professional oversight when implementing AI. LataMed AI's technologies are designed to enhance human capabilities and support informed decision-making, not replace the independent judgment of professionals. Additional topics will include integration of AI into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations in deploying technology in healthcare settings.
The company will also discuss the continued development of its healthcare technology ecosystem, including CardioAI, PulmoAI, and NeuroAI, which are AI-supported platforms designed to assist in cardiovascular, pulmonary, and neurological health information evaluation and management. These platforms are subject to ongoing development, testing, regulatory requirements, and commercial implementation.
Dr. Kevin Rodan Levy stated, "Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of AI in healthcare and systems engineering. Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America."
Management believes that engagement with universities can increase awareness of emerging healthcare technologies, encourage responsible discussion, and strengthen relationships with future professionals. The company views this participation as a chance to better understand perspectives as it develops digital health and AI-supported solutions for the region.
LataMed AI's participation aligns with its broader strategy of supporting education, professional collaboration, and responsible adoption of digital healthcare infrastructure. The company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums. Participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, nor does it guarantee future collaborations or financial benefits.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
